Tebipenem pivoxil crystalline forms, compositions including the same, methods of manufacture, and methods of use
Inventors
Jain, Akash • Hecker, Evan • Edwards, Richard • Bonnaud, Thierry
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-12098155-B2
Publication Date
2024-09-24
Expiration Date
Abstract
The disclosure is directed to new crystalline tebipenem pivoxil salt forms, including a crystalline tebipenem pivoxil ethane sulfonate salt form (Form A), a crystalline tebipenem pivoxil ketoglutarate salt form (Form A), tebipenem pivoxil maleate salt forms (Form A and Form B), a tebipenem pivoxil malate salt form (Form A), a tebipenem pivoxil methane sulfonate salt form (Form B), a tebipenem pivoxil hydrobromide salt form (Form B), and a tebipenem pivoxil edisylate salt form (Form A). The disclosure also includes a composition, comprising a crystalline tebipenem pivoxil salt and a pharmaceutically acceptable carrier and further includes a method for treating an antibiotic resistant bacterial infection, comprising administering to a patient in need of such treatment a therapeutically effective amount of a crystalline tebipenem pivoxil salt.
Core Innovation
The disclosed subject matter relates to crystalline solid forms of tebipenem pivoxil salt, including a crystalline tebipenem pivoxil methane sulfonate salt form. The disclosure provides identification and characterization of individual salt forms based on solid-state analytical measurements, including XRPD diffractograms obtained from a Cu Kα source with characteristic 2θ values and the corresponding peak sets shown in figures.
The disclosure further includes thermal characterization using DSC profiles, with stated endotherms and temperatures to support identification of particular crystalline salt forms. Purity assessment is described using HPLC for the individual salt forms. Additional solid-state behaviors are addressed, including deliquescence and solid-state conversion between polymorph/salt forms after storage under specified conditions.
Formulation scope is also described, including crystalline tebipenem pivoxil salt together with pharmaceutically acceptable carrier(s), and the use of such compositions in oral dosage forms, parenteral dosage forms, other dosage forms, and kits/medicament packaging. A controlled-release concept is also mentioned within the formulation framework. Treatment is described for antibiotic-resistant bacterial infections, including urinary tract infections and Gram-negative bacterial infections with examples of organisms.
Claims Coverage
The provided independent claims define two related crystalline salt-form characterizations for tebipenem pivoxil methane sulfonate, primarily using XRPD from a Cu Kα source. The inventive features are characterized by specific XRPD peak positions (with stated 2θ values and tolerance), and dependent claim coverage extends to additional thermal characterization (DSC) and composition/dosage/treatment refinements as described in the provided claim summaries.
Crystalline methane sulfonate salt form defined by characteristic XRPD 2θ values of FIG. 12 (Cu Kα)
A crystalline tebipenem pivoxil methane sulfonate salt form in which the XRPD of the form, obtained from a Cu Kα source, has the characteristic 2θ values of FIG. 12.
Crystalline methane sulfonate salt form defined by specified XRPD peak sets (Cu Kα)
A crystalline tebipenem pivoxil methane sulfonate salt form characterized by an XRPD diffractogram obtained from a Cu Kα source comprising peaks at specified 2θ values: (i) 9.6, 12.6, 15.4, 19.4, and 22.2±0.2 degrees 2θ or (ii) 10.9, 13.9, 17.2, 20.4, and 23.6±0.2 degrees 2θ.
Overall, the independent claims focus on defining a specific tebipenem pivoxil methane sulfonate crystalline salt form by XRPD-based phase identification using Cu Kα peak positions. The dependent coverage, as reflected in the provided claim summaries, additionally incorporates DSC thermal profile identification and further narrows to pharmaceutical composition and dosage/treatment context.
Stated Advantages
Documented Applications
No documented applications found
Interested in licensing this patent?